BioXcel Therapeutics: FDA Accepts IGALMI Application FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

BioXcel Therapeutics: FDA Accepts IGALMI Application: FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts. 👈 Read full analysis #BioXcelTherapeutics #IGALMI #FDANews #Pharmaceuticals #DrugApproval

IGALMI Sees Remarkable Growth in Market Accessibility for Mental Health Treatments The IGALMI market is expanding rapidly, driven by its unique formulation for treating agitation in mental health conditions. This article explores its impact.

IGALMI Sees Remarkable Growth in Market Accessibility for Mental Health Treatments #United_States #Las_Vegas #IGALMI #Dexmedetomidine #BioXcel_Therapeutics